Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

• Status: Completed
• Trial end date: 2017-09-13
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device).

The secondary objective of this study is to assess patient-reported satisfaction with the BETACONNECT device.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Interferon beta-1b; Interferon-beta; Interferons

Criteria

Inclusion Criteria:

• Male and females greater than or equal to 18 years of age

• Diagnosis of RRMS according to revised McDonald Criteria (2010) or (CIS)

• Prescribed BETASERON (note: decision to treat with BETASERON must be made independent of participation in this study)

• Confirmation of insurance coverage for BETASERON treatment

• Access to a personal computer to complete online patient satisfaction survey at Week 6

Exclusion Criteria:

• Currently enrolled in a clinical trial or other observational study for Multiple Sclerosis treatment

• Documented substance abuse within the previous 6 months prior to study enrollment

• Any major laboratory value abnormality that the investigator believes would preclude the patient from participating in the study

• Any medical disorder, condition or history that in the opinion of the investigator would impair the patient's ability to participate in or complete the study

• Pregnant or nursing